Scholarlink

<p>Extended-spectrum β-lactamase (ESBL)-producing bacteria pose significant therapeutic challenges, necessitating the development of alternative antimicrobial agents such as metal nanoparticles. Among 58 bacterial isolates from clinical samples at the National Cancer Institute (Cairo, Egypt), eight ESBL-producing strains were identified (six <i>E. coli</i> and two <i>K. pneumoniae</i>) using phenotypic screening and VITEK 2 system, representing preliminary laboratory findings. GC-MS analysis of <i>Salvia officinalis</i> aqueous extract revealed 16 compounds, with rosmarinic acid (20.41%) as the major constituent. The successful green synthesis of cobalt oxide nanoparticles (CoO-NPs) using <i>S. officinalis</i> was confirmed through UV-visible spectroscopy showing a characteristic peak at 520&#xa0;nm, HRTEM revealing particle sizes of 10–50&#xa0;nm, and XRD patterns matching the CoO phase. FTIR spectroscopy confirmed the presence of metal-oxygen bonds and surface functionalization. CoO-NPs demonstrated significant antibacterial activity against ESBL-producing isolates with inhibition zones ranging from 24 to 26&#xa0;mm and MIC values of 0.312–0.625&#xa0;mg/ml while enhancing the efficacy of several antibiotics, particularly rifampicin, meropenem, and gentamicin. Antioxidant assays revealed free radical scavenging activity with IC50 values of 513.7&#xa0;µg/mL and 208&#xa0;µg/mL for DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2′-azino-di-[3-ethylbenzthiazoline sulfonate (6)]), respectively. Cytotoxicity studies against normal cell lines showed dose-dependent effects with IC50 values of 303.526&#xa0;µg/mL for VERO cells and 253.19&#xa0;µg/mL for OEC cells, with significant morphological changes observed at 500&#xa0;µg/mL. These preliminary laboratory findings suggest that <i>S. officinalis</i>-mediated CoO-NPs represent a promising therapeutic agent against ESBL-producing bacteria, offering a balance between antimicrobial efficacy and biological safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bio-generated CoO-NPs from Salvia officinalis: a promising tool against ESBL-producing bacteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Mohamed H. Kalaba,
  • Ahmed A. Elrefaey,
  • Mohamed E. Saber,
  • Mohamed H. Sharaf,
  • Saad A. Moghannem,
  • Amira Salah El-Din Youssef

摘要

Extended-spectrum β-lactamase (ESBL)-producing bacteria pose significant therapeutic challenges, necessitating the development of alternative antimicrobial agents such as metal nanoparticles. Among 58 bacterial isolates from clinical samples at the National Cancer Institute (Cairo, Egypt), eight ESBL-producing strains were identified (six E. coli and two K. pneumoniae) using phenotypic screening and VITEK 2 system, representing preliminary laboratory findings. GC-MS analysis of Salvia officinalis aqueous extract revealed 16 compounds, with rosmarinic acid (20.41%) as the major constituent. The successful green synthesis of cobalt oxide nanoparticles (CoO-NPs) using S. officinalis was confirmed through UV-visible spectroscopy showing a characteristic peak at 520 nm, HRTEM revealing particle sizes of 10–50 nm, and XRD patterns matching the CoO phase. FTIR spectroscopy confirmed the presence of metal-oxygen bonds and surface functionalization. CoO-NPs demonstrated significant antibacterial activity against ESBL-producing isolates with inhibition zones ranging from 24 to 26 mm and MIC values of 0.312–0.625 mg/ml while enhancing the efficacy of several antibiotics, particularly rifampicin, meropenem, and gentamicin. Antioxidant assays revealed free radical scavenging activity with IC50 values of 513.7 µg/mL and 208 µg/mL for DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2′-azino-di-[3-ethylbenzthiazoline sulfonate (6)]), respectively. Cytotoxicity studies against normal cell lines showed dose-dependent effects with IC50 values of 303.526 µg/mL for VERO cells and 253.19 µg/mL for OEC cells, with significant morphological changes observed at 500 µg/mL. These preliminary laboratory findings suggest that S. officinalis-mediated CoO-NPs represent a promising therapeutic agent against ESBL-producing bacteria, offering a balance between antimicrobial efficacy and biological safety.